Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

DCB Outcomes After Non-Compliant Balloon Vessel Preparation With or Without Scoring in Patients With Femoropopliteal Arterial Disease (DASBAD-NC)

12 augustus 2026 bijgewerkt door: Marc Sirvent

Drug-coated Balloon Angioplasty After Non-Compliant Balloon Vessel Preparation With or Without Scoring for Femoropopliteal Arterial Disease: A Randomized Controlled Trial

The aim of this clinical trial is to determine whether vessel preparation with a non-compliant scoring balloon before drug-coated balloon (DCB) angioplasty provides superior procedural and clinical outcomes compared with vessel preparation using a non-compliant plain balloon in patients with chronic limb-threatening ischaemia (CLTI) undergoing femoropopliteal endovascular intervention.

The main questions the study aims to answer are:

  • Does non-compliant scoring balloon vessel preparation reduce the need for bailout stenting during the index procedure?
  • Does it improve primary patency after DCB angioplasty?
  • Does it improve clinically relevant outcomes such as wound healing, freedom from clinically driven target lesion revascularisation, limb salvage and health-related quality of life?
  • Does it provide procedural and economic advantages compared with non-compliant plain balloon vessel preparation?

Participants will be randomly assigned to undergo vessel preparation using either a non-compliant plain balloon or the DKutting™ non-compliant scoring balloon, followed by angioplasty with the Legflow XP™ drug-coated balloon. Patients will undergo clinical, duplex ultrasound and quality-of-life follow-up for 24 months.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

The DASBAD-NC trial is a prospective, multicentre, randomised, patient-blinded, controlled clinical investigation designed to compare two vessel preparation strategies before drug-coated balloon (DCB) angioplasty for femoropopliteal arterial disease in patients with chronic limb-threatening ischaemia (Rutherford classification 4-5).

Eligible patients with significant atherosclerotic femoropopliteal disease (≥50% stenosis or chronic total occlusion) will be randomised in a 1:1 ratio, after successful guidewire crossing of the target lesion and confirmation of all eligibility criteria, to one of two treatment strategies:

  • Vessel preparation using a non-compliant plain balloon (PBA arm), followed by Legflow XP™ drug-coated balloon angioplasty.
  • Vessel preparation using the DKutting™ non-compliant scoring balloon (SB arm), followed by Legflow XP™ drug-coated balloon angioplasty.

Vessel preparation will be performed using a 1:1 balloon-to-reference vessel diameter ratio with a minimum inflation time of 180 seconds. Predilatation with a smaller balloon will only be permitted if the allocated study balloon cannot cross the lesion. Drug-coated balloon angioplasty will subsequently be performed using the Legflow XP™ drug-coated balloon according to the study protocol. Bailout stenting will only be permitted in the presence of residual stenosis ≥30% and/or flow-limiting dissection after DCB treatment.

The co-primary endpoints are bailout stenting during the index procedure and primary patency at 12 months. Secondary endpoints include freedom from clinically driven target lesion revascularisation, target limb major amputation, all-cause mortality, wound healing, health-related quality of life, procedural success, slow-flow phenomenon, procedural costs and other prespecified clinical and imaging outcomes.

Duplex ultrasound follow-up examinations will undergo blinded central review by an independent duplex ultrasound core laboratory. Procedural angiographic outcomes will undergo an independent blinded quality assurance review after database lock by experienced investigators according to the prespecified study methodology. Clinical events will be adjudicated by an independent Clinical Events Committee according to prespecified endpoint definitions.

Patients will be followed for 24 months after the index procedure.

Studietype

Ingrijpend

Inschrijving (Geschat)

142

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • ≥18 years of age.
  • Rutherford class 4-5.
  • Estimated life expectancy >1 year, per investigator's judgment.
  • Significant atherosclerotic lesions (≥50% stenosis or chronic total occlusion) in the femoropopliteal segment, including in-stent restenosis.
  • Signed informed consent.
  • Willingness to comply with follow-up visits.
  • ≥1 patent infragenicular artery (<50% stenosis) at the end of the procedure.
  • Target vessel diameter ≤8 mm.

Exclusion Criteria:

  • Pregnant or planning pregnancy during the study.
  • Participation in another drug/device trial.
  • Inability to cross the target lesion with a guidewire. Successful crossing is defined as advancement of the guidewire tip distal to the target lesion without vessel perforation or flow-limiting dissection.
  • Inadequate treatment of proximal lesion (>30% residual stenosis).
  • Severe calcification of the target vessel [group 4 of Fanelli classification17 defined as circumferential calcification (270º-360º)], evidenced before contrast injection or digital subtraction angiography.
  • Thrombus in the target vessel.
  • Anastomotic stenosis of a bypass.
  • Use of atherectomy, thrombectomy, laser, or similar devices.
  • Prior or planned above-the-ankle amputation of the target limb.
  • Coagulopathy, hypercoagulable state, bleeding diathesis, platelets <80 000/µL or >700 000/µL, or other blood disorder.
  • Gastrointestinal bleeding requiring transfusion within 3 months.
  • Contraindication to antiplatelet/anticoagulant/thrombolytic therapy.
  • Acute coronary syndrome within 30 days.
  • Stroke or TIA within 90 days.
  • Hypersensitivity/contraindication to nitinol.
  • Comorbidities precluding treatment or follow-up (per investigator).
  • Hypersensitivity/allergy to contrast not manageable medically.
  • Hypersensitivity/allergy to heparin, aspirin, paclitaxel, clopidogrel, or other antiplatelet/anticoagulant agents.
  • Contraindication to dual antiplatelet therapy.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Non-compliant plain balloon (PBA)
  • Vessel preparation using non-compliant plain balloon
  • Definitive treatment: drug-coated balloon angioplasty (Legflow XP™; Manufacturer: Cardionovum GmbH Bonn, Germany).
Apparaat: Non-compliant Plain Balloon angioplasty (PBA)
The intervention consists of preparing the artery with a non-compliant plain balloon before using the DCB (Legflow XP™; Manufacturer: Cardionovum GmbH Bonn, Germany).
Andere namen:
  • Controlegroep
  • Group 0
Actieve vergelijker: Scoring balloon (SB)
  • Vessel preparation using non-compliant scoring balloon (DKutting™; Manufacturer: DK Medical Technology Co., Ltd., Suzhou, China)
  • Definitive treatment: drug-coated balloon angioplasty (Legflow XP™; Manufacturer: Cardionovum GmbH Bonn, Germany) as definitve treatment.
Apparaat: Non-compliant Scoring Balloon Angioplasty (SB)
The intervention consists of preparing the artery with a non-compliant scoring balloon (DKutting™; Manufacturer: DK Medical Technology Co., Ltd., Suzhou, China) before using the DCB (Legflow XP™; Manufacturer: Cardionovum GmbH Bonn, Germany) as definitve treatment.
Andere namen:
  • Interventie groep
  • Groep 1
  • Behandelingsgroep

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Bailout stenting
Tijdsspanne: At index procedure
The need for bailout stenting during the index procedure, defined as stent implantation due to residual stenosis >30% or a flow-limiting dissection (type C according to the Kobayashi classification)
At index procedure
Primary Patency
Tijdsspanne: At 12 months
Primary patency at 12 months defined as absence of ≥50% restenosis (peak systolic velocity ratio<2.5) and no clinically driven target lesion revascularisation (CD-TLR), as adjudicated by the duplex core laboratory and the Clinical Events Committee.
At 12 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Device success
Tijdsspanne: During the index procedure
Device success, defined as successful delivery, inflation, and retrieval of the assigned balloon catheter, resulting in a residual stenosis <30% without flow-limiting dissection (FLD) on final angiography.
During the index procedure
Technical success
Tijdsspanne: During the index procedure.
Technical success, defined as successful use of a device or technique to re-establish vessel patency with a residual stenosis <30% by visual estimation and <50% by duplex during the index procedure.
During the index procedure.
Procedural cost
Tijdsspanne: During the index procedure
Procedural cost, defined as the total acquisition cost (€) of all lesion preparation balloons (including adjunctive predilatation balloons, if required) and bailout stents used during the index procedure for the target lesion.
During the index procedure
Slow-flow phenomenon
Tijdsspanne: During the index procedure
Slow-flow phenomenon, defined as an angiographic reduction in antegrade flow occurring after DCB inflation compared with the immediately preceding angiogram, in the absence of residual stenosis >30%, flow-limiting dissection, or vasospasm. The presence or absence of slow-flow phenomenon will be determined by the independent blinded angiographic review.
During the index procedure
Procedural success
Tijdsspanne: Occurring <24 hours and <1 month of the index procedure.
Procedural success, defined as technical success with absence of rupture, distal embolization, thrombosis, access complications, or major adverse cardiovascular events. These events should be listed as occurring <24 hours and <1 month of the procedure.
Occurring <24 hours and <1 month of the index procedure.
Freedom from device and procedure-related death
Tijdsspanne: Until 30 days post-procedure
Freedom from device and procedure-related death through 30 days post-procedure.
Until 30 days post-procedure
Freedom from Major Adverse Events (MAE)
Tijdsspanne: Up to 24 months post-procedure

Freedom from Major Adverse Events (MAE) up to 24 months post-procedure.

MAE are defined as the composite of:

  • Major Adverse Cardiovascular Events (MACE), including all-cause death, myocardial infarction, stroke, or major bleeding requiring transfusion or surgical intervention.
  • Major Adverse Limb Events (MALE), including above-the-ankle target limb amputation or major re-intervention involving the target lesion, defined as new bypass graft, jump/interposition graft revision, thrombectomy, thrombolysis or endovascular reintervention.
Up to 24 months post-procedure
Primary patency
Tijdsspanne: At 6 and 24 months post-procedure
Primary patency at 6 and 24 months post-procedure, defined as absence of ≥50% restenosis (peak systolic velocity ratio<2.5) and no CD-TLR, as adjudicated by the duplex core laboratory and the Clinical Events Committee (CEC).
At 6 and 24 months post-procedure
Freedom from CD-TLR
Tijdsspanne: Up to 24 months post-procedure

Freedom from CD-TLR up to 24 months post-procedure.

  • CD-TLR is defined as any repeat revascularisation procedure performed to maintain or restore patency within the treated segment, including 5 mm proximal and 5 mm distal to the edges of the originally treated lesion, due to clinical deterioration.
  • Clinical deterioration is defined as a ≥1-category worsening in Rutherford classification, impaired wound healing, or new or recurrent ulceration or rest pain attributable to the target lesion
Up to 24 months post-procedure
Change in EQ-5D questionnaire
Tijdsspanne: Up to 24 months post-procedure
Change in EQ-5D questionnaire from baseline up to 24 months post-procedure
Up to 24 months post-procedure
Amputation free survival
Tijdsspanne: Up to 24 months post-procedure.

Amputation free survival up to 24 months post-procedure.

• Amputation free survival is defined as survival without above-the-ankle amputation of the target limb.
Up to 24 months post-procedure.
Wound healing evolution
Tijdsspanne: Up to 24 months post-procedure

Wound healing evolution up to 24 months post-procedure, assessed according to the following predefined ordinal classification:

  • Healed: Complete epithelialisation of the target wound maintained for at least 14 consecutive days.
  • Improved: Reduction in target wound area >50% compared with baseline.
  • Unchanged: Increase or decrease in target wound area ≤50% compared with baseline.
  • Worsened: Increase in target wound area >50% compared with baseline. The target wound will be defined as the largest or clinically most relevant wound identified at baseline.
Up to 24 months post-procedure
Wound healing time
Tijdsspanne: Days from the index procedure to complete epithelialisation of the target wound

Wound healing time is defined as the number of days from the index procedure to complete epithelialisation of the target wound, without drainage or need for dressing, as assessed by the treating physician.

• Major amputation of the index limb or death prior to complete wound healing will be considered failure of the wound healing endpoint.
Days from the index procedure to complete epithelialisation of the target wound
Change in Rutherford classification
Tijdsspanne: Up to 24 months post-procedure.
Change in Rutherford classification up to 24 months post-procedure.
Up to 24 months post-procedure.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Marc Sirvent

Medewerkers

Cardionovum GmbH
DK Medical Technology (Suzhou) Co., Ltd.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 december 2029

Studie voltooiing (Geschat)

1 december 2030

Studieregistratiedata

Eerst ingediend

9 augustus 2026

Eerst ingediend dat voldeed aan de QC-criteria

9 augustus 2026

Eerst geplaatst (Werkelijk)

13 augustus 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

14 augustus 2026

Laatste update ingediend die voldeed aan QC-criteria

12 augustus 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • DASBAD-NC

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Data collected within the DASBAD-NC study will be made available to researchers upon reasonable request. Access to the data is controlled to ensure the protection of participant privacy and compliance with applicable data protection laws and regulations. Data will be shared upon revision and approval based on scientific merit by the DASBAD-NC management group (which includes a qualified statistician) of a detailed proposal for their use. The data required for the approved, specified purposes and the trial protocol will be provided after the completion of a data-sharing agreement that will be set up by the principal investigator and his team. All data provided will be anonymized to respect the privacy of patients who have participated in the trial. Estimated timeframe for response will be within 30 days. Requests for data should be addressed to the sponsor and PI (msirvent@fphag.org).

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren